CytomX Therapeutics, Inc.
CTMX evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Market Cap:
- $771.4M
- Lead Asset:
- CX-2029 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CTMX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTMX
CytomX Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated therapies using its PROBODY platform, with a Phase 2 candidate (CX-2029) and a Phase 1 candidate (CX-2051) in its pipeline, and a key collaboration with Regeneron.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$771.4M
Cash Runway
—
Lead Asset
CX-2029 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 2 clinical trials for CytomX Therapeutics, Inc..
CytomX Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated therapies using its PROBODY platform, with a Phase 2 candidate (CX-2029) and a Phase 1 candidate (CX-2051) in its pipeline, and a key collaboration with Regeneron.
- Cash & equivalents of $17.2M as of 2026-06-30 [sec].
- Total revenue of $1.4M and net income of -$20.7M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $302.1M as of 2026-06-30 [sec].
- Phase 2 candidate CX-2029 (CD71-targeting ADC) is in development; the DLBCL cohort was later deprioritized [pipeline].
- Phase 1 candidate CX-2051 (EpCAM-targeting ADC) received FDA IND clearance in January 2024 [pipeline].
What works
- The PROBODY platform enables conditionally activated therapies, potentially improving the therapeutic window for T-cell engagers and ADCs [sec_mda · as of 2026-05-07].
- The expanded Regeneron collaboration (amended May 2026) included a $37.0M target selection payment in July 2026, with potential for up to six additional future targets [sec_mda · as of 2026-08-06].
- Preclinical data for CX-908 (dually-masked PROBODY TCE) showed a 100-fold improvement in tolerability vs. an unmasked molecule [sec_mda · as of 2026-05-07].
What to weigh
- The company reported a net loss of -$20.7M for the period ending 2026-06-30, with only $1.4M in total revenue [sec].
- Cash & equivalents of $17.2M as of 2026-06-30 may be limited relative to ongoing R&D and clinical trial expenses [sec].
- The Phase 2 candidate CX-2029 had its DLBCL cohort deprioritized, and the AbbVie co-development partnership was terminated [pipeline].
- The company is still in clinical-stage with no approved products, and its forward-looking statements are subject to risks and uncertainties [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2024-04-02 · Phase 1 start for CX-2051 — Initiation of the Phase 1 study for CX-2051 in advanced solid tumors.
- 2024-08-28 · Phase 1 start for CX-801 — Initiation of the Phase 1 study for CX-801 as monotherapy and in combination with PD1 inhibition.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $17.2M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- No approved products — CytomX has no marketed products; all candidates are in clinical or preclinical stages, with no guaranteed regulatory approval [sec_mda · as of 2026-05-07].
- Dependence on collaborations — Key programs rely on partners (e.g., Regeneron); termination or changes could disrupt pipeline progress [sec_mda · as of 2026-08-06].
- Clinical trial risks — Phase 2 candidate CX-2029 had a deprioritized cohort and terminated partnership, indicating potential development hurdles [pipeline].
What to watch
- CX-2051 Phase 1 data update expected in Q1 2026 [news · published 2025-11-06].
- CX-2051 Phase 1b CRC combination study with bevacizumab starting in Q1 2026 [news · published 2025-11-06].
- CX-801 Phase 1 combination study with KEYTRUDA (pembrolizumab) in melanoma ongoing [news · published 2025-11-06].
- Potential additional target nominations from Regeneron under the expanded collaboration [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run CytomX Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CytomX Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.26 · 0% dilution
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
179
Total value held
$907.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 31,955,637 | $150.2M |
| kynam capital management, lp | 15,013,093 | $70.6M |
| bank of america corp /de/ | 10,202,785 | $48.0M |
| perceptive advisors llc | 10,098,824 | $47.5M |
| venrock adviser, llc | 9,982,124 | $46.9M |
| vanguard capital management llc | 8,733,118 | $41.0M |
| point72 asset management, l.p. | 7,875,390 | $37.0M |
| state street corp | 5,663,408 | $26.6M |
| citadel advisors llc | 5,406,193 | $25.4M |
| blackrock, inc. | 5,228,280 | $24.6M |
Showing top 10 of 179 institutional holders of CytomX Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 15.5%
- Days to cover
- 7.0
- Shares short
- 29,742,798
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CTMX short interestGovernance
Frequently asked questions
What is the AI investment thesis for CytomX Therapeutics, Inc.?
CytomX Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated therapies using its PROBODY platform, with a Phase 2 candidate (CX-2029) and a Phase 1 candidate (CX-2051) in its pipeline, and a key collaboration with Regeneron.
What is CytomX Therapeutics, Inc.'s lead drug candidate?
CytomX Therapeutics, Inc.'s most advanced tracked candidate is CX-2029 (Phase 2) for Solid and hematologic cancers with CD71 (transferrin receptor) expression; Phase 2 expansion included sqNSCLC, HNSCC, E/GEJ cancers, and DLBCL (DLBCL cohort later deprioritized).
Who is the CEO of CytomX Therapeutics, Inc.?
Dr. Sean A. McCarthy DPHIL is the chief executive officer of CytomX Therapeutics, Inc. (CTMX).
Where is CytomX Therapeutics, Inc. headquartered?
CytomX Therapeutics, Inc. (CTMX) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does CytomX Therapeutics, Inc. focus on?
CytomX Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.